GILD · News · 20261030N

Revenue Performance and Mix

GILEAD SCIENCES, INC. · 2026-10-30 · Importance 56 · Surprise 46 · No source text

Gilead’s third-quarter 2026 revenue increased 6.8% year over year to $8.3 billion, while product sales rose 13% to $8.29 billion. HIV, Trodelvy and Livdelzi supported growth, while Veklury sales fell 69% to $86 million. Royalty, contract and other revenue declined to $11 million from $424 million because prior-year intellectual property revenue did not recur.

Key facts

• Gilead's third-quarter 2026 royalty, contract and other revenues fell to $11 million from $424 million as prior-year intellectual property revenues did not recur. source
• Gilead's third-quarter 2026 product sales grew 13% to $8.29 billion, led by HIV drugs, Trodelvy and Livdelzi. source
• Gilead reported third-quarter 2026 revenue of $8.3 billion, up 6.8% year over year. source
• Gilead's third-quarter 2026 revenue rose 6.8% to $8.3 billion, above the Zacks Consensus Estimate of $7.82 billion. source
• Gilead's third-quarter 2026 base business sales increased 16% year over year, the company's strongest growth in more than a decade. source

Impact estimates